He won't talk about how any pharmas are going with their trials etc etc etc. So that rules a lot of Q 's out.
He can't say much about any future contracts if there are any. The market won't believe it until it hears it and they will be a 4-6 hr news story.
He can't talk about production because that won't happen until second half 2018 or later.
Very unlikely to talk about any future funding in detail.
Maybe some news on flogging off the other platforms.
JR may not be AS, but I don't expect any Q's to be answered with much detail.
Same old same old.
UNS Price at posting:
5.7¢ Sentiment: Hold Disclosure: Held
